PET及PET-CT在监测肿瘤治疗效果中的价值

陈香; 赵晋华

陈香 , 赵晋华

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 6: (354-358)

引用本文:

Citation:

PET及PET-CT在监测肿瘤治疗效果中的价值

陈香,
赵晋华^,

200080 上海, 上海交通大学附属第一人民医院核医学科

通讯作者: 赵晋华, zjhl963@gmail.com

中图分类号: R817.4

Value of PET and PET-CT for monitoring tumor therapy

CHEN Xiang,
ZHAO Jin-hua^,

Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China

Corresponding author: ZHAO Jin-hua, zjhl963@gmail.com

CLC number: R817.4

摘要: ¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)PET和PET-CT既能准确鉴别肿瘤残留与纤维化,又能通过定量评价治疗前后¹⁸F-FDG摄取的变化来早期预测疗效和评价预后,指导临床及时调整治疗方案,因此越来越多地被用于监测肿瘤放化疗疗效。目前已建立了一些应用PET和PET-CT监测肿瘤疗效的具体方法,研究结果显示,PET及PET-CT在监测肿瘤疗效方面存在明显的优势,但也存在问题。
- 氟脱氧葡萄糖F18 /
- 体层摄影术,发射型计算机 /
- 体层摄影术,X线计算机 /
- 肿瘤
Abstract: ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET or PET-CT is an accurate test for differentiating residual viable tumor tissue from therapy-induced changes in tumor. Furthermore, quantitative assessment of therapy-induced changes in tumor ¹⁸F-FDG uptake may allow the prediction of tumor response. Treatment may be adjusted according to tumor response. So it is increasingly used to monitor tumor response in patients undergoing chemotherapy and chemoradiotherapy. Here we focused on practical aspects of ¹⁸F-FDG PET or PET-CT for treatment monitoring and on the existing advantages and challenges.
- Fluorodeoxyglucose F18 /
- Tomography,emission-computed /
- Tomography,X-ray computed /
- Neoplasm
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med, 2006, 47(3):451-469.
[2]	Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2005, 23(21):4652-4661.
[3]	Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 2005, 16(9):1514-1523.
[4]	Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 2006, 107(1):52-59.
[5]	Cerfolio R J, Bryant AS, Winokur TS. et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 2004, 78(6):1903-1909.
[6]	Pottgen C, Levegrun S, Theegarten D, et al. Value of ¹⁸F-fluoro-2deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1):97-106.
[7]	Nahmias C, Hanna WT. Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with ¹⁸F-FDG PET-CT. J Nucl Med, 2007, 48(5):744-751.
[8]	Stroobants S, Goeminne J, Seegers M, et al. ¹⁸F-DG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinih mesylate (Glivec). Eur J Cancer,2003, 39(14):2012-2020.
[9]	Goerres GW, Stupp R, Barghouth G. et al. The value of PET, CT and in-line PET-CT in patients with gastrointestinal stromal tumours:long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 2005, 32(2):153-162.
[10]	Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dualmodality PET-CT imaging for monitoring of imatinib (ST1571)therapy in patients with gastrointestinal stromal tumors. J Nacl Med, 2004, 45(3):357-365.
[11]	Buyse M, Thirion P, Carlson RW, et al.Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer:a meta-analysis, Meta-Analysis Group in Cancer. Lancet, 2000, 356(9227):373-378.
[12]	Goffin J, Baral S, Tu D, et al. Objective responsed in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res, 2005, 11(16):5928-5934.
[13]	Jerusalem G, Hustinx R, Beguin Y. et al. Evaluation of therapy for lymphoma. Semin Nucl Med, 2005, 35(3):186-196.
[14]	Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med, 2005, 46(6):983-995.
[15]	Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14):2651-2657.
[16]	Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of ¹⁸F-FDG PET as an indictor of therapeutic response in patients in national cancer institute trials. J Nucl Med, 2006, 47(6):1059-1066.
[17]	Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002, 346(4):235-242.
[18]	Spaepen K, Stroobants S, Dupont P, et al. Early re-staging positron emission tomography with ¹⁸F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol,2002, 13(9):1356-1363.
[19]	Haioun C,Itti E, Rahmouni A, et al.[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET) in aggressive lymphoma:an early prognostic tool for predicting patient outcome. Blood, 2005, 106(4):1376-1381.
[20]	Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2(stage Ⅲa) non-small cell lung cancer after neoadjuvant chemoradiotherapy:a prospective study. J Thorac Cardiovasc Surg, 2006, 131(6):1229-1235.
[21]	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med,2005, 353(2):123-132.
[22]	Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer:results from a randomized, placebo-controlled, multicentre study(Iressa Survival Evalustion in LungCancer).Lancet, 2005, 366(9496):1527-1537.
[23]	Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 2004, 64(11):3892-3899.
[24]	Demetri GD, yon Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7):472-480.
[25]	Weber WA, Figlin R. Monitoring cancer treatment with PET-CT:does it make a difference?. J Nucl Med, 2007, 48(Suppl 1):36S-44S.
[26]	Young H, Baum R, Cremerius U, et al. Measurement of clinical and sublinical tumour response using[¹⁸F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 1999, 35(13):1773-1782.
[27]	WeberWA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 1999, 40(11):1771-1777.
[28]	Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging, 2006, 33(Suppl 1):27-37.

[1]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[2]	张玉娜 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
[3]	杨吉刚 , 李春林 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT在食管癌中的. 国际放射医学核医学杂志, 2007, 31(1): 31-33.
[4]	赵德善 , 乔振华 . ¹⁸F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(3): 141-144.
[5]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[6]	孙琳 , 高再荣 , 张永学 . ¹⁸F-氟代脱氧葡萄糖PET-CT用于恶性肿瘤治疗疗效评估与监测. 国际放射医学核医学杂志, 2006, 30(6): 328-331.
[7]	张悦 . ¹⁸F-氟脱氧葡萄糖PET和PET-CT在结直肠癌术后复发或转移中的应用价值. 国际放射医学核医学杂志, 2007, 31(1): 34-36.
[8]	曹霞 , 谢爱民 , 莫逸 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT在非小细胞肺癌临床分期及经治患者疗效评价中的应用. 国际放射医学核医学杂志, 2008, 32(4): 214-216.
[9]	宋少莉 , 黄钢 . ¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
[10]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.

点击查看大图

计量

文章访问数: 1298
HTML全文浏览量: 61
PDF下载量: 2

PET及PET-CT在监测肿瘤治疗效果中的价值

陈香
赵晋华^,

通讯作者: 赵晋华, zjhl963@gmail.com

200080 上海, 上海交通大学附属第一人民医院核医学科

收稿日期: 2007-09-10

关键词:

摘要: ¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)PET和PET-CT既能准确鉴别肿瘤残留与纤维化,又能通过定量评价治疗前后¹⁸F-FDG摄取的变化来早期预测疗效和评价预后,指导临床及时调整治疗方案,因此越来越多地被用于监测肿瘤放化疗疗效。目前已建立了一些应用PET和PET-CT监测肿瘤疗效的具体方法,研究结果显示,PET及PET-CT在监测肿瘤疗效方面存在明显的优势,但也存在问题。